Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial

References

• Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49) [UK Prospective Diabetes Study (UKPDS) Group]. J Am Med Assoc 1999;281:2005–12
   PubMed Web of Science ®Google Scholar
• DeFronzo RA. Pharmacologic therapy for type 2 diabetes 2 diabetes mellitus. Ann Intern Med 1999;131:281–303
   PubMed Web of Science ®Google Scholar
• Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: 2 diabetes: scientific review. J Am Med Assoc 2002;287:360–72
   PubMed Web of Science ®Google Scholar
• Erle G, Lovise S, Stocchiero C, et al. A comparison of preconstituted, fixed combinations of low-dose glyburide plus metformin versus high-dose glyburide alone in the treatment of type 2 diabetic patients. Acta Diabetol 1999;36:61–5
   PubMed Web of Science ®Google Scholar
• Wyne KL, Drexler AJ, Miller JL, Bell DS, Braunstein S, Nuckolls JG. Constructing an algorithm for managing type 2 diabetes. Focus on role of the thiazolidinediones. Postgrad Med 2003;[Spec No:63–72, review]
   Google Scholar
• Davidson MB, Peters AL. An overview of metformin in the treatment of type 2 diabetes mellitus. Am J Med 1997;102: 99–110
   PubMed Web of Science ®Google Scholar
• Cusi K, Defronzo R. Metformin: a review of its metabolic effects. Diabetes Rev 1998;6:89–131
   Google Scholar
• Luna B, Feinglos MN. Oral agents in the management of type 2 diabetes mellitus. Am Fam Phys 2001;63:1747–56
   PubMed Web of Science ®Google Scholar
• Wagman AS, Nuss JM. Current therapies and emerging targets for the treatment of diabetes. Curr Pharm Des 2001;7:417–50
   PubMed Web of Science ®Google Scholar
• Wolffenbuttel BH, Gomis R, Squatrito S, Jones NP, Patwardhan RN. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients. Diabetic Med 2000;17: 40–7
   Google Scholar
• Fonseca V, Rosenstock J, Pattwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. J Am Med Assoc 2000;283:1695–702
   PubMed Web of Science ®Google Scholar
• Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study: the Pioglitazone 027 Study Group. Clin Ther 2000;22:1395–409
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Brown A, Fischer J, et al. Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes. Diabetes Care 1998;21:2050–5
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus: the Multicenter Metformin Study Group. New Engl J Med 1995;333:541–9
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352: 854–65
   Google Scholar
• Schade DS, Jovanovic L, Schneider J. A placebo-controlled, randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful. J Clin Pharmacol 1998;38: 636–41
   Google Scholar
• Korytkowski M, Thomas A, Reid L, Tedesco MB, Gooding WE, Gerich J. Glimepiride improves both first and second phases of insulin secretion in type 2 diabetes. Diabetes Care 2002;25:1607–11
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Samols E, Muchmore DB, Schneider J. Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients [Glimepiride Study Group]. Diabetes Care 1996;19:1194–9
   PubMed Web of Science ®Google Scholar
• Rosenkranz B, Profozic V, Metelko Z, Mrzljak V, Lange C, Malerczyk V. Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment. Diabetologia 1996;39:1617–24
   PubMed Web of Science ®Google Scholar
• Holstein A, Plaschke A, Egberts EH. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev 2001;17: 467–73
   Google Scholar
• Riddle MC, McDaniel P, Bugos C. First-dose C-peptide response and risk of hypoglycemia are lower with glimepiride than glyburide. Diabetes Care 2001;50:A129
   Google Scholar
• Kabadi UM, Kabadi MU. Improvement in lipids with glimepiride in type 2 diabetes mellitus. Diabetes Res 2001;35:155–62
   Google Scholar
• Bugos C, Austin M, Viereck C, Atherton T. Long-term treatment of type 2 diabetes mellitus with glimepiride is weight neutral: a meta-analysis. Diabetes Res Clin Pract 1999;50:S47
   Google Scholar
• Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose–response study [The Pioglitazone 001 Study Group]. Diabetes Care 2000;23:1605–11
   PubMed Web of Science ®Google Scholar
• Feeny D, Furlong W, Boyle M, Torrance GW. Multi-attribute health status classification systems. Health Utilities Index. Pharmacoeconomics 1995;7:490–502
   PubMed Web of Science ®Google Scholar
• Medical Economics. Red book 2003 drug topics: the pharmacist’s trusted companion for more than a century (red book drug topics). Toronto (ON): Thomson Healthcare; 2003
   Google Scholar
• American Medical Association. Medicare Resource Based Relative Value Scale (RBRVS): the physicians guide 2003. Chicago (IL); 2003
   Google Scholar
• Anon. DRG expert, 2003: a comprehensive reference to the DRG classification system, 19th ed. Ingenix; 2002
   Google Scholar
• Boccuzzi SJ, Wogen J, Fox J, Sung JC, Shah AB, Kim J. Utilization of oral hypoglycemic agents in a drug-insured US population. Diabetes Care 2001;24:1411–5
   PubMed Web of Science ®Google Scholar
• Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study [The Pioglitazone 027 Study Group]. Clin Ther 2000:22:1395–409
   PubMed Web of Science ®Google Scholar
• Charpentier G, Fleury F, Kabir M, Vaur L, Halimi S. Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients. Diabetic Med 2001;18: 828–34
   Google Scholar
• Rendell MS, Glazer NB, Ye Z. Combination therapy with pioglitazone plus metformin or sulfonylurea in patients with type 2 diabetes: influence of prior antidiabetic drug regimen. J Diabetes Complications 2003;17: 211–7
   Google Scholar
• Kahn SE. Clinical review 135. The importance of beta-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab 2001;86:4047–58
   Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. UK prospective diabetes study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. Diabetes 1995;44: 1249–58
   Google Scholar
• Yki-Jarvinen H. Thiazolidinediones. New Engl J Med. 2004;351:1106–18
   Google Scholar
• Ginsberg H, Plutzky J, Sobel BE. A review of metabolic and cardiovascular effects of oral antidiabetic agents: beyond glucose-level lowering. J Cardiovasc Risk 1999;6:337–46
   Google Scholar
• Lebovitz HE, Banerji MA. Insulin resistance and its treatment by thiazolidinediones. Recent Prog Horm Res 2001;56: 265–94
   PubMedGoogle Scholar
• Riddle MC, Rosenstock JR. Oral monotherapy and combination therapy. In: Cefalu W, Gerich JE, LeRoith D, editors. The CADRE handbook of diabetes management. New York: Medical Information Press; 2004. p. 127–44
   Google Scholar
• Mudaliar S, Henry R. Combination therapy for type 2 diabetes. Endocrine Practice 1999;5:208–19
   PubMedGoogle Scholar
• Avandamet [package insert]. Physicians’ desk reference. Montvale (NJ): Thomson PDR; 2005. p. 1433–8
   Google Scholar
• Avandia [package insert]. Physicians’ desk reference. Montvale (NJ): Thomson PDR; 2005.p. 1438–43
   Google Scholar
• Actos [package insert]. Physicians’ desk reference. Montvale (NJ): Thomson PDR; 2005. p. 3181–5
   Google Scholar
• Spiegelman BM. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 1988;47:507–14
   Google Scholar
• Adams M, Montague CT, Prins JB, et al. Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation. J Clin Invest 1997;100:3149–53
   PubMed Web of Science ®Google Scholar
• Zhang BB, Moller DE. New approaches in the treatment of type 2 diabetes. Curr Opin Chem Biol 2000;4:461–7
   PubMed Web of Science ®Google Scholar